Sponsor:
Sanofi
Code:
NCT07756957
Conditions
Acne
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Acne mRNA (messenger ribonucleic acid) vaccine
Placebo
Brief summary:
Conditions
Acne
Study ID
NCT07756957
Start date
Oct 14, 2026
Status verified date
Nov, 2026
Completion date
Feb 19, 2029
Anticipated
Primary completion date
Jul 19, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Enrollment
410 participants
Anticipated
Allocation
Randomized
Intervention Model
Sequential
Primary purpose
Prevention
Arms
experimental: Dose 1 sub-cohort - Group 1
placebo comparator: Dose 1 sub-cohort - Group 2
experimental: Dose 2 sub-cohort - Group 3
placebo comparator: Dose 2 sub-cohort - Group 4
experimental: Dose 3 sub-cohort - Group 5
placebo comparator: Dose 3 sub-cohort - Group 6
experimental: Dose 1 main cohort - Group 7
experimental: Dose 2 main cohort - Group 8
experimental: Dose 3 main cohort - Group 9
placebo comparator: Main cohort - Group 10
Interventions
Acne mRNA (messenger ribonucleic acid) vaccine
Placebo
Primary outcome measure
Central contacts
Locations
Investigational Site Number : 1240001
Recruiting
Edmonton, Alberta, Canada, T5J 3S9
Investigational Site Number : 1240013
Recruiting
Edmonton, Alberta, Canada, T6w 0J5
Investigational Site Number : 1240009
Recruiting
Vancouver, British Columbia, Canada, V6C 0C3
Sponsor
Sanofi
Last update posted
Nov 18, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Sanofi on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.